Figure 3.
Mechanisms by which SGLT-2 inhibitors reduce the risk of CVD. SGLT-2—sodium–glucose co-transporter-2; CVD—cardiovascular disease; AGEs—advanced glycation end products.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.